These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 10604379

  • 1. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
    Elsässer-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W, Wetterauer U.
    J Urol; 2000 Jan; 163(1):296-9. PubMed ID: 10604379
    [Abstract] [Full Text] [Related]

  • 2. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
    Elsässer-Beile U, Leiber C, Wolf P, Lucht M, Mengs U, Wetterauer U.
    J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
    [Abstract] [Full Text] [Related]

  • 5. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 6. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
    Saint F, Irani J, Salomon L, Legrand P, Abbou CC, Chopin D.
    Prog Urol; 2001 Dec; 11(6):1242-50. PubMed ID: 11859659
    [Abstract] [Full Text] [Related]

  • 7. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U, Kölble N, Grussenmeyer T, Wetterauer U, Schultze-Seemann W.
    Anticancer Res; 1998 Dec; 18(3B):1883-90. PubMed ID: 9677439
    [Abstract] [Full Text] [Related]

  • 8. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH.
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [Abstract] [Full Text] [Related]

  • 9. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 10. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar 15; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 11. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P, Błaszczyk J, Fijałkowski P, Sierakowska-Fijałek A, Niemirowicz J, Kasprzak A, Baj Z.
    Pol Merkur Lekarski; 2005 Oct 15; 19(112):526-8. PubMed ID: 16379317
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN, Dewald B, Baggiolini M, Studer UE.
    J Urol; 1997 Oct 15; 158(4):1340-4. PubMed ID: 9302115
    [Abstract] [Full Text] [Related]

  • 13. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
    Wen R, Zhou G, Xie S, Lian B, Sun X, Chen J.
    Zhonghua Wai Ke Za Zhi; 1998 Apr 15; 36(4):247-8. PubMed ID: 11825381
    [Abstract] [Full Text] [Related]

  • 14. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK.
    J Urol; 2001 Dec 15; 166(6):2142-7. PubMed ID: 11696723
    [Abstract] [Full Text] [Related]

  • 15. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S.
    Urol Int; 2005 Dec 15; 75(2):114-8. PubMed ID: 16123563
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan 15; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 17. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, Sylvester R, European Organization for Research and Treatment of Cancer Genitourinary Group.
    J Urol; 2001 Feb 15; 165(2):401-3. PubMed ID: 11176382
    [Abstract] [Full Text] [Related]

  • 18. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
    de Boer EC, De Reijke TM, Vos PC, Kurth KH, Schamhart DH.
    Clin Infect Dis; 2000 Sep 15; 31 Suppl 3():S109-14. PubMed ID: 11010835
    [Abstract] [Full Text] [Related]

  • 19. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation.
    Pavlovich CP, Kräling BM, Stewart RJ, Chen X, Bochner BH, Luster AD, Poppas DP, O'Donnell MA.
    J Urol; 2000 Jun 15; 163(6):2014-21. PubMed ID: 10799249
    [Abstract] [Full Text] [Related]

  • 20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr 15; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.